Myomo (NYSEAMERICAN:MYO) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Tuesday.

According to Zacks, “Myomo, Inc. is a commercial stage medical robotics company. It offers expanded mobility which suffering from neurological disorders and upper limb paralysis. The company develops and markets the MyoPro(R) product line of lightweight, non-invasive, powered arm braces to restore function in the paralyzed or weakened arms and hands of individuals. Myomo, Inc. is headquartered in Cambridge,Massachusetts. “

Several other analysts have also issued reports on the company. HC Wainwright set a $12.00 target price on Myomo and gave the stock a “buy” rating in a report on Tuesday, August 14th. Roth Capital reissued a “buy” rating on shares of Myomo in a research report on Thursday, November 8th.

MYO opened at $1.81 on Tuesday. Myomo has a 52-week low of $1.60 and a 52-week high of $5.63.

Myomo (NYSEAMERICAN:MYO) last released its earnings results on Monday, November 5th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.01). The company had revenue of $0.61 million during the quarter, compared to analyst estimates of $0.82 million.

Myomo Company Profile

Myomo, Inc, a commercial stage medical robotics company, designs, develops, and produces myoelectric braces or orthotics for people suffering with neuromuscular disorders in the United States. It offers MyoPro, a powered upper limb orthosis that supports the arm, as well as restores function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain injury, spinal cord injury, ALS, or other neuromuscular disease or injury.

Recommended Story: Are all No-Load Funds Equal?

Get a free copy of the Zacks research report on Myomo (MYO)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Myomo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myomo and related companies with's FREE daily email newsletter.